U31402-A-U301
ET21000394
U31402-A-U301: HERTHENA–Lung02 : Ph III_patrimumab deruxtecan _ CBNPC EGFR +
Description of the study :
U31402-A-U301: HERTHENA–Lung02: A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-Based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-Mutated (EGFRm) Non-Small Cell Lung Cancer (NSCLC) After Failure of EGFR Tyrosine Kinase Inhibitor (TKI) Therapy
Coordinating doctor : Dr PEROL Maurice
Co-investigators : Dr NEIDHARDT - BERARD Eve Marie ; Dr GUEVARA Hemerson ; Dr FAYETTE Jérôme ; Dr AVRILLON Virginie ; Dr MASTROIANNI Bénédicte ; Dr SWALDUZ Aurélie ; Dr BOUSSAGEON Maxime ; Dr KARABAJAKIAN Andy ; Dr GILLE Romane ; Dr DECROISETTE Chantal ; Dr MUNOZ UNCETA Nerea ;
Promoter : DAIICHI SANKYO PHARMA DEVELOPMENT
Study link : internationale